Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
Anna Z. Mykytyn, Melanie Rissmann, Adinda Kok, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Timothée Bruel, Jérôme Hadjadj, Piet Maes, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1297-1302
Open Access | Times Cited: 290
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
Leanne P. M. van Leeuwen, Corine H. GeurtsvanKessel, Pauline M. Ellerbroek, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1949-1957
Open Access | Times Cited: 61
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history
Wei Wang, Sabrina Lusvarghi, Rahul Subramanian, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 12, pp. 1745-1758.e7
Open Access | Times Cited: 61
Mapping the antigenic diversification of SARS-CoV-2
Karlijn van der Straten, Denise Guerra, Marit J. van Gils, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 56
SARS-CoV-2 variants – Evolution, spike protein, and vaccines
Kai-Wei K. Chen, Daniel Tsung‐Ning Huang, Li‐Min Huang
Biomedical Journal (2022) Vol. 45, Iss. 4, pp. 573-579
Open Access | Times Cited: 51
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
John E. Bowen, Kaitlin R. Sprouse, Alexandra C. Walls, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 42
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
Ngoc H. Tan, Daryl Geers, Roos S. G. Sablerolles, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 901-913
Open Access | Times Cited: 28
Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant
Jan‐Stephan Sanders, A. Lianne Messchendorp, Rory D. de Vries, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e188-e199
Open Access | Times Cited: 38
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
Neeltje van Doremalen, Jonathan E. Schulz, Danielle R. Adney, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa
Heather J. Zar, Rae MacGinty, Lesley Workman, et al.
EClinicalMedicine (2022) Vol. 53, pp. 101655-101655
Open Access | Times Cited: 35
SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022
Samuel M. S. Cheng, Chris Ka Pun Mok, Karl CK Chan, et al.
Eurosurveillance (2022) Vol. 27, Iss. 18
Open Access | Times Cited: 34
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant
David Niklas Springer, Thomas Perkmann, Claudia Jani, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 30
Analysis of SARS-CoV-2 Omicron Neutralization Data up to 2022-01-28
Antonia Netzl, Sina Türeli, Eric B. LeGresley, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 29
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Emanuele Andreano, Ida Paciello, Silvia Marchese, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 27
Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
Qianqian Li, Mingjie Zhang, Ziteng Liang, et al.
MedComm (2022) Vol. 3, Iss. 2
Open Access | Times Cited: 26
Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review
Giorgio Tiecco, Samuele Storti, Stefania Arsuffi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7315-7315
Open Access | Times Cited: 22
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
Shô Miyamoto, Takeshi Arashiro, Akira Ueno, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 105969-105969
Open Access | Times Cited: 12
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants
Sabari Nath Neerukonda, Richard Wang, Russell Vassell, et al.
Journal of Virology (2022) Vol. 96, Iss. 17
Open Access | Times Cited: 17
Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents
Naomi S. Coombes, Kevin R. Bewley, Yann Le Duff, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 633-633
Open Access | Times Cited: 10
Distinct antigenic properties of the SARS-CoV-2 Omicron lineages BA.4 and BA.5
Brian J. Willett, Ashwini Kurshan, Nazia Thakur, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 15
Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine
Amanda K. Debes, Shaoming Xiao, Emily R. Egbert, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 15
Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
Petrus Jansen van Vuren, Alexander J. McAuley, Michael J. Kuiper, et al.
Viruses (2022) Vol. 14, Iss. 4, pp. 800-800
Open Access | Times Cited: 11
BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants
Annika Rössler, Antonia Netzl, Ludwig Knabl, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 11
Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant
Jan‐Stephan Sanders, A. Lianne Messchendorp, Rory D. de Vries, et al.
SSRN Electronic Journal (2022)
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top